Skin and soft tissue infections due to methicillin-resistant staphylococcus aureus: Role of tigecycline

Clinical Infectious Diseases

Volumn 52, Issue 12, 2011, Pages 1468-1469

  Curcio, Daniel ^a  

^a Instituto Sacre Cour   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

AZTREONAM; TIGECYCLINE; VANCOMYCIN;

ABDOMINAL INFECTION; ANTIBIOTIC THERAPY; BACTERIAL SKIN DISEASE; BACTERIOSTASIS; COMPLICATED INTRAABDOMINAL INFECTION; COMPLICATED SKIN AND SKIN TISSUE INFECTION; DIABETIC FOOT; DRUG EFFICACY; ENDOCARDITIS; ERADICATION THERAPY; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; LETTER; MENINGITIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RISK ASSESSMENT; SOFT TISSUE INFECTION; VENTILATOR ASSOCIATED PNEUMONIA;

ANTI-BACTERIAL AGENTS; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MINOCYCLINE; SOFT TISSUE INFECTIONS; STAPHYLOCOCCAL SKIN INFECTIONS; TREATMENT OUTCOME;

EID: 79958147906     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir192     Document Type: Letter

References (10)

1. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin- resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18-55.
2. Tigecycline Evaluation and Surveillance Trial (TEST). http://www.testsurveillance. com. Accessed 1 February 2011.
3. Stein GE, Craig WA. Tigecycline: a critical analysis. Clin Infect Dis 2006; 43: 518-24. (Pubitemid 44157163)
4. Mendes RE, Sader HS, Deshpande L, et al. Antimicrobial activity of tigecycline against community-acquired methicillin-resistant Staphylococcus aureusisolates recovered from North American medical centers. Diagn Microbiol Infect Dis 2008; 60: 433-6. (Pubitemid 351380768)
5. Florescu I, Beuran M, Dimov R, et al. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycinresistant enterococci: a phase 3-multicentre, double-blind, randomized study. J Antimicrob Chemother 2008; 62(suppl 1): i17-28.
6. Gardiner D, Dukart G, Cooper A, et al. Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 phase III clinical trials. Clin Infect Dis 2010; 50:229-38.
7. Lipsky BA, Kollef MH, Miller LG, et al. Predicting bacteremia among patients hospitalized for skin and skin-structure infections: derivation and validation of a risk score. Infect Control Hosp Epidemiol 2010; 31:828-37.
8. Finberg RW, Moellering RC, Tally FP, et al. The importance of bactericidal drugs: future directions in infectious disease. Clin Infect Dis 2004; 39:1314-20. (Pubitemid 39458517)
9. FDA. FDA Drug Safety Communication: increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections. http://www. fda.gov/Drugs/DrugSafety/ucm224370.htm. Accessed 1 September 2010.
10. Curcio D, Fernández F, Duret F. Tigecycline use in critically ill older patients: case reports and critical analysis. J Am Geriatr Soc 2007; 55:312-3. (Pubitemid 46184415)